Dyne Therapeutics, Inc. (DYN) closed the last trading session at $9.91, gaining 10.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $38.21 indicates a 285.6% upside potential.The mean estimate comprises 17 short-term price targets with a standard deviation of $14.79. While the lowest estimate of $9.00 indicates a 9.2% decline from the current price level, the most optimistic anal ...

Shares of Genius Sports Limited (GENI) have gained 0.7% over the past four weeks to close the last trading session at $10.17, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $12.82 indicates a potential upside of 26.1%.The average comprises 17 short-term price targets ranging from a low of $11.00 to a high of $15.00, with a standard deviation of $1.13. While the lowest estimate ...

Nomad Foods (NOMD) closed the last trading session at $17.49, gaining 0.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $24 indicates a 37.2% upside potential.The mean estimate comprises six short-term price targets with a standard deviation of $2.37. While the lowest estimate of $20.00 indicates a 14.4% increase from the current price level, the most optimistic analyst expects ...

HNI (HNI) closed the last trading session at $51.83, gaining 1.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $68.75 indicates a 32.7% upside potential.The average comprises four short-term price targets ranging from a low of $60.00 to a high of $80.00, with a standard deviation of $8.54. While the lowest estimate indicates an increase of 15.8% from the current price level, the ...

Geo Group (GEO) closed the last trading session at $26.1, gaining 9.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $41.8 indicates a 60.2% upside potential.The mean estimate comprises five short-term price targets with a standard deviation of $6.42. While the lowest estimate of $35.00 indicates a 34.1% increase from the current price level, the most optimistic analyst expects t ...

公司股价表现与目标价分析 - Mineralys Therapeutics Inc (MLYS) 最新收盘价为14 26美元 过去四周累计上涨1 9% [1] - 华尔街分析师给出的平均目标价为36 25美元 隐含154 2%上行空间 最低目标价15美元(5 2%涨幅) 最高目标价48美元(236 6%涨幅) [1][2] - 8个目标价的标准差为11 25美元 标准差越小表明分析师共识度越高 [2][9] 分析师目标价的可信度 - 实证研究表明 分析师目标价对股价预测的准确性长期存疑 常误导投资者 [7] - 华尔街分析师可能因商业利益(如维护客户关系)设定过度乐观的目标价 [8] - 投资者不应仅依赖目标价决策 但低标准差的目标价集群可作为研究起点 [9][10] 盈利预测修正与评级 - 当前财年Zacks共识盈利预测30天内上调1 6% 无负面修正 [11][12] - MLYS获Zacks2(买入)评级 位列4000多只股票前20% 短期上行潜力获量化模型支持 [13] - 盈利预测修正趋势与股价走势存在强相关性 形成基本面支撑 [11][14] 投资价值判断依据 - 尽管目标价可靠性存疑 但其指示的价格方向仍具参考价值 [14] - 盈利预测上修共识强化了股价上行逻辑 但需结合其他基本面因素综合判断 [4][11]

Shares of Alvotech (ALVO) have gained 0.3% over the past four weeks to close the last trading session at $9.16, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $17.5 indicates a potential upside of 91.1%.The mean estimate comprises four short-term price targets with a standard deviation of $7. While the lowest estimate of $14.00 indicates a 52.8% increase from the current price ...

Shares of On Holding (ONON) have gained 0.3% over the past four weeks to close the last trading session at $51.64, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $64.64 indicates a potential upside of 25.2%.The mean estimate comprises 22 short-term price targets with a standard deviation of $6.45. While the lowest estimate of $50.00 indicates a 3.2% decline from the current pri ...

股价目标分析 - Oneok Inc (OKE) 最新收盘价为80 38美元 过去四周上涨0 7% 华尔街分析师给出的平均目标价103 35美元 隐含28 6%上行空间 [1] - 17份目标价预测的标准差为15 23美元 最低预测87美元(隐含8 2%涨幅) 最高预测147美元(隐含82 9%涨幅) 标准差反映分析师意见分歧程度 [2] - 分析师目标价存在局限性 实证研究表明其预测准确性存疑 投资者不应仅依赖该指标决策 [3][7] 盈利预测修正 - 分析师普遍上调EPS预测 显示对公司盈利前景的乐观情绪 盈利预测修正趋势与股价走势存在强相关性 [4][11] - Zacks共识预测过去一个月上调3 3% 其中2家机构调高预测 1家调低 [12] - OKE当前获Zacks评级2级(买入) 位列4000多只股票前20% 该评级基于盈利预测等四项因素 历史回溯表现优异 [13] 目标价可信度研究 - 学术研究发现分析师目标价常具误导性 与实际股价走势关联性弱 与投行商业利益存在潜在冲突 [7][8] - 低标准差显示分析师对股价方向共识度高时 可作为基本面研究的起点 但不应视为绝对预测 [9][10] - 尽管目标价可靠性存疑 但其隐含的价格方向指引仍具参考价值 [14]

股价表现与分析师目标价 - Enovix Corporation(ENVX)股价过去四周上涨87.4%至15.93美元 华尔街分析师平均目标价25.92美元隐含62.7%上行空间 [1] - 12个短期目标价的标准差为24.62美元 最低目标价9美元隐含43.5%跌幅 最高目标价100美元隐含527.8%涨幅 [2] - 分析师对盈利预期的上调形成强烈共识 当前年度Zacks共识预期过去30天上升0.2% [11][12] 分析师目标价的有效性 - 目标价作为投资决策单一依据存在局限性 分析师设定的目标价常因商业利益关系被夸大 [3][8] - 全球多所大学研究表明 目标价误导投资者的频率高于指导作用 实际预测准确性存疑 [7] - 低标准差显示分析师对股价变动方向与幅度高度一致 可作为基本面研究的起点 [9] 盈利预期与评级 - ENVX获Zacks评级2级(买入) 位列4000多只股票前20% 短期上行潜力获确认 [13] - 盈利预期修正趋势与短期股价走势存在强相关性 近期EPS预期上调强化看涨逻辑 [11][14] - 单一分析师上调全年盈利预期 无负面修正 形成乐观预期氛围 [12]